BMO Capital Markets Reiterates “Outperform” Rating for Alnylam Pharmaceuticals, Inc. (ALNY)
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)‘s stock had its “outperform” rating reissued by analysts at BMO Capital Markets in a research note issued on Wednesday. They presently have a $99.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $105.00. BMO Capital Markets’ price objective points to a potential upside of 34.35% from the company’s current price.
Several other research analysts also recently weighed in on the stock. Stifel Nicolaus restated a “buy” rating and set a $56.00 price target (up previously from $47.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, August 10th. Chardan Capital restated a “buy” rating and set a $124.00 price target (down previously from $131.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, August 10th. Morgan Stanley raised their price target on shares of Alnylam Pharmaceuticals from $46.00 to $50.00 and gave the stock an “equal weight” rating in a report on Thursday, August 10th. ValuEngine upgraded shares of Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Finally, Barclays PLC raised their price target on shares of Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the stock an “equal weight” rating in a report on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $83.79.
Alnylam Pharmaceuticals (ALNY) traded up 1.60% on Wednesday, reaching $73.69. The company had a trading volume of 1,279,425 shares. The stock’s 50-day moving average is $82.17 and its 200-day moving average is $67.35. Alnylam Pharmaceuticals has a 52 week low of $31.38 and a 52 week high of $89.45. The company’s market capitalization is $6.76 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.22) by $0.12. Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The business had revenue of $15.93 million during the quarter, compared to analysts’ expectations of $23.86 million. During the same period in the previous year, the company posted ($1.05) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 82.9% compared to the same quarter last year. Equities research analysts forecast that Alnylam Pharmaceuticals will post ($5.18) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/06/alnylam-pharmaceuticals-inc-alny-earns-outperform-rating-from-bmo-capital-markets.html.
Institutional investors have recently added to or reduced their stakes in the company. Broadfin Capital LLC purchased a new position in shares of Alnylam Pharmaceuticals in the second quarter valued at $14,453,000. Verition Fund Management LLC bought a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at $1,060,000. The Manufacturers Life Insurance Company boosted its stake in Alnylam Pharmaceuticals by 7.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 167 shares during the last quarter. EcoR1 Capital LLC bought a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at $831,000. Finally, BlueCrest Capital Management Ltd bought a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at $1,304,000. 94.27% of the stock is owned by institutional investors.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.